Vertex cystic fibrosis drug approved for another 500 U.S. patients

The U.S. Food and Drug Administration has approved Kalydeco by Vertex Pharmaceuticals for use in about 500 more cystic fibrosis patients than previously. Kalydeco is the Boston pharmaceutical company's only approved drug, following it's decision last year to discontinue its hepatitis C drug due to competition. The drug is approved to treat several different gene mutations that cause the disease in about 1,150 patients who make up about 4 percent of CF patients in the U.S. The new approval for patients…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Source Type: news